Study protocol of the GLOW study: maximising treatment options for recurrent glioblastoma patients by whole genome sequencing-based diagnostics—a prospective multicenter cohort study

BACKGROUND: Glioblastoma (GBM), the most common glial primary brain tumour, is without exception lethal. Every year approximately 600 patients are diagnosed with this heterogeneous disease in The Netherlands. Despite neurosurgery, chemo -and radiation therapy, these tumours inevitably recur. Current...

Descripción completa

Detalles Bibliográficos
Autores principales: van Opijnen, Mark P., Broekman, Marike L. D., de Vos, Filip Y. F., Cuppen, Edwin, van der Hoeven, Jacobus J. M., van Linde, Myra E., Compter, Annette, Beerepoot, Laurens V., van den Bent, Martin J., Vos, Maaike J., Fiebrich, Helle-Brit, Koekkoek, Johan A. F., Hoeben, Ann, Kho, Kuan H., Driessen, Chantal M. L., Jeltema, Hanne-Rinck, Robe, Pierre A. J. T., Maas, Sybren L. N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9636658/
https://www.ncbi.nlm.nih.gov/pubmed/36333718
http://dx.doi.org/10.1186/s12920-022-01343-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9636658/
https://www.ncbi.nlm.nih.gov/pubmed/36333718
http://dx.doi.org/10.1186/s12920-022-01343-4

Ejemplares similares